1193687-87-4 Usage
Description
Raltegravir, also known as R100300, is a potent human immunodeficiency virus (HIV) integrase inhibitor. It is an antiviral medication that works by blocking the integration of the HIV virus into the host's DNA, thereby preventing the virus from replicating and spreading. Raltegravir is characterized by its effectiveness in treating HIV and its low incidence of side effects, making it a valuable component in the fight against the virus.
Uses
Used in Pharmaceutical Industry:
Raltegravir is used as an antiviral agent for the treatment of HIV infection. It is particularly effective in inhibiting the integration of the HIV virus into the host's DNA, which is a crucial step in the viral replication process. By blocking this integration, raltegravir helps to prevent the spread of the virus and reduce the viral load in the body.
Additionally, raltegravir is used as a component in combination therapies for HIV, often in conjunction with other antiretroviral drugs. This combination approach enhances the overall effectiveness of the treatment and helps to minimize the development of drug resistance.
Check Digit Verification of cas no
The CAS Registry Mumber 1193687-87-4 includes 10 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 7 digits, 1,1,9,3,6,8 and 7 respectively; the second part has 2 digits, 8 and 7 respectively.
Calculate Digit Verification of CAS Registry Number 1193687-87:
(9*1)+(8*1)+(7*9)+(6*3)+(5*6)+(4*8)+(3*7)+(2*8)+(1*7)=204
204 % 10 = 4
So 1193687-87-4 is a valid CAS Registry Number.
1193687-87-4Relevant articles and documents
Identification, synthesis, and strategy for minimization of potential impurities observed in raltegravir potassium drug substance
Patil, Gulabrao D.,Kshirsagar, Siddheshwar W.,Shinde, Shivnath B.,Patil, Pankaj S.,Deshpande, Mangesh S.,Chaudhari, Ashok T.,Sonawane, Swapnil P.,Maikap, Golak C.,Gurjar, Mukund K.
, p. 1422 - 1429 (2012/10/29)
Multiple sources of anticipated degradation and process impurities of raltegravir potassium drug substance observed during the laboratory optimization and later during its bulk synthesis are described in this article. The impurities were monitored by UPLC, and their structures are tentatively assigned on the basis of fragmentation patterns in LC-MS and NMR spectroscopy. Most of the impurities are synthesized, and their assigned constitutions were confirmed by co-injection in UPLC. In addition to the formation, synthesis, and characterization, strategy for minimizing these impurities to the level accepted by ICH is also described. We feel that our study will be helpful to the generic industry for obtaining chemically pure raltegravir potassium.
